Imaging Agents: A Global Strategic Business Report
San Jose, CA (Vocus/PRWEB) February 22, 2011
Though the recession had a significant impact on the imaging equipment market, with marked slowdown on purchase of capital equipment, the impact on the imaging agents market has been less severe, as stated by the new market research report on Imaging Agents. This is mainly due to the widespread availability of existing equipment in key markets including Europe and the US and increasing focus on diagnostic examinations that facilitate early identification of the disease and its treatment. Demand for imaging agents moves in sync with diagnosis and management of several age-related diseases including cancer, cardiovascular disease, and neurological disease. Prevalence of these diseases has augmented in recent years with increase in percentage of senior population worldwide. Moreover, spurred by expansion of imaging modalities in new clinical applications and technological advancements, the imaging agents segment is expected to recover quickly and achieve significant growth rates.
The US represents the largest imaging agents market worldwide. Japan and Europe are the two other significant markets for imaging agents globally. The recession has augmented the growing clout of developing nations such as India and China in the global arena. With the US embracing itself for the healthcare reforms and Europe recovering from the huge deficits due to the bailouts, firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe that enjoy attractive budgets at the disposal.
Global imaging agent market is expected to witness revolutionary changes if targeted MRI imaging, a technology currently under developmental stage, comes to fruition. Targeted MRI contrast agents combine the specific localization of molecular targets with the advanced spatial resolution and noninvasiveness of MRIs, thereby greatly enhancing the range of MRI market applications. The technology could make imaging a definitive procedure for detection of cardiovascular ailments as well as tumors. Research is underway for developing targeted MRI contrast agents on the lines of targeted SPECT imaging agents, which are already available for clinical applications. However, MRI’s inherently low sensitivity necessitates a large concentration of contrast agents at the targeted site while also maintaining the specificity of cell recognition and high affinity.
Contrast agents have evolved significantly, starting initially from barium and iodine based agents that were used for over half a century to newer variants compatible with modern imaging techniques such as CT, MRI, ultrasound, and PET. Highly developed contrast agents used nowadays bring brighter and clearer images for greater accuracy in medical diagnosis. Increased market penetration of medical imaging equipment is expected to lead to significant opportunities for the use of contrast agents. X-ray contrast media, the dominant segment, is ceding market space to relatively emerging segments including MRI, Ultrasound and diagnostic radiopharmaceuticals. The global ultrasound contrast media market is forecast to hold lucrative opportunities. Based on the gas microbubble technology, ultrasound agents produce less adverse effects in comparison to that of gadolinium or iodine-based contrast agents. Reimbursement issues and procedural volumes are two key factors that exert a significant impact on market dynamics. Increasing concerns over radiation exposure is resulting in innovation of faster scanners for imaging, which in turn exacerbates the need for faster contrast media injectors. These new injectors are likely to curtail the amount of contrast agent used.
Radiopharmaceuticals are driving growth owing to an increasing number of PET procedures and nuclear medicine along with the rising amount of professional preferences for high value-added biotechnology-derived substances serving the purpose of enhancing image resolution and detail.
The global marketplace comprises several well-established players in different market segments. No single player has managed to emerge as the leader across the entire spectrum of contrast media and agents, with different companies occupying leadership position in different categories. Leading market participants profiled in the report include AMAG Pharmaceuticals Inc, GE Healthcare, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Bracco Group, Covidien, Cytogen Corp, Daiichi Sankyo Company Limited, Eisai Co Ltd., Guerbet Group, and Lantheus Medical Imaging.
The research report titled "Imaging Agents: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, challenges, product profile, players, competition, technological developments, research and development activity, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets such as United States, Japan, France, Germany, the UK, Italy, Asia, Latin America and the Middle East. Product segments analyzed include Contrast Media (X-ray imaging agents, MRI imaging agents and Ultrasound imaging agents) and Diagnostic Radiopharmaceuticals.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Imaging_Agents_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #